Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Thymoma-associated Myasthenia Gravis
50%
B Cell Subsets
50%
Primary Care
50%
Fecal Hemoglobin Concentration
50%
Thymoma
50%
Prospective Cohort Study
50%
Patient Outcomes
50%
Fecal Immunochemical Test for Hemoglobin
50%
College Student Learning
50%
Bowel Symptoms
50%
Colorectal Cancer
42%
Significant Bowel Disease
21%
Fecal Immunochemical Test
21%
Clinical Assessment
14%
High-risk Adenoma
14%
Inflammatory Bowel Disease
14%
Record Linkage
14%
Peripheral Blood
13%
Myasthenia Gravis
13%
CD19+
7%
Tumor Microenvironment
7%
CT Colonoscopy
7%
Obstructive Colorectal Cancer
7%
Patient Risk
7%
Colonoscopy
7%
Cancer Cases
7%
Rule-out Test
7%
Cancer Registry
7%
Clinical Cutoff
7%
Incident Cases
7%
Feces
7%
Anonymized
7%
Single Center
7%
Scottish
7%
Secondary Care
7%
Low Intensity Focused Ultrasound
7%
Abnormal Lymphocyte
5%
CD19+ B Cells
5%
CD20+ B Cells
5%
Peripheral Tumor
5%
CD19
5%
B Cells
5%
CD20
5%
Medicine and Dentistry
Occult Blood Test
50%
Prospective Cohort Study
50%
Hemoglobin Determination
50%
Primary Health Care
50%
Colorectal Carcinoma
50%
Hemoglobins
50%
Enteropathy
21%
Adenoma
14%
Gene Linkage
14%
Colonoscopy
14%
Clinical Assessment
14%
Inflammatory Bowel Disease
14%
Cancer Registry
7%
Secondary Care
7%
Prevalence
7%
Feces
7%
Immunology and Microbiology
Thymus Cancer
100%
Myasthenia gravis
100%
B Lymphocyte Subpopulation
50%
Regulatory B Cells
50%
Follicular B Helper T Cells
50%
CD19
24%
B Cell
24%
CD20
9%